头颈癌根治性放疗后长期患者报告结局的剂量学因素
本研究前瞻性收集53例头颈癌放疗患者的PRO数据,用QLQ-C30和QLQ-H&N35量表评估健康相关生活质量(HRQOL)。治疗结束6个月后按HRQOL恶化程度分为严重恶化组与轻度恶化组,分析剂量学参数与HRQOL恶化的关系。结果显示,上咽缩肌和腮腺平均剂量与社交进食困难和咳嗽的严重恶化相关,中咽缩肌剂量与恶心呕吐的严重恶化相关。
要点
- 上咽缩肌和腮腺平均剂量与社交进食困难和咳嗽的严重恶化相关
- 中咽缩肌平均剂量与恶心呕吐的严重恶化相关
- 采用Bonferroni校正,P<0.0013为统计学显著
核心结论
- 上咽缩肌和腮腺剂量与社交进食困难和咳嗽导致的HRQOL严重恶化相关。
- 中咽缩肌剂量与恶心呕吐导致的HRQOL严重恶化相关。
研究设计与样本
- 前瞻性收集53例头颈癌放疗患者的PRO数据。
- 使用QLQ-C30和QLQ-H&N35量表评估HRQOL。
- 治疗结束6个月后按HRQOL恶化程度分为严重恶化组和轻度恶化组。
- 评估患者相关或剂量学相关因素与HRQOL恶化的关系。
主要发现
- 社交进食困难严重恶化组与轻度恶化组的上咽缩肌平均剂量分别为62.5 Gy vs 54.2 Gy(p=0.00029)。
- 社交进食困难严重恶化组与轻度恶化组的腮腺平均剂量分别为24.1 Gy vs 20.5 Gy(p=0.000056)。
- 咳嗽严重恶化组与轻度恶化组的上咽缩肌平均剂量分别为61.5 Gy vs 54.1 Gy(p=0.0012)。
- 咳嗽严重恶化组与轻度恶化组的腮腺平均剂量分别为24.2 Gy vs 20.3 Gy(p=0.00043)。
- 恶心呕吐严重恶化组与轻度恶化组的中咽缩肌平均剂量分别为61.9 Gy vs 58.4 Gy(P=0.00059)。
关键数值与推荐
- 采用Bonferroni校正,P<0.0013认为有统计学显著性。
- HRQOL恶化程度以治疗结束6个月后评估,分为严重恶化和轻度恶化。
临床怎么用
- 头颈癌根治性放疗计划设计时,应关注上咽缩肌、中咽缩肌和腮腺的平均剂量。
- 限制上咽缩肌和腮腺剂量可能减少社交进食困难和咳嗽的长期严重恶化。
- 限制中咽缩肌剂量可能减少恶心呕吐的长期严重恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to explore the relationships between dosimetric parameters of organs at risk and patient-reported outcomes (PRO) after radiotherapy of patients with head and neck cancer. METHODS: PRO data of 53 patients with head and neck cancer treated with radiotherapy were prospectively collected. These data concerned health-related quality of life (HRQOL) and were collected using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and head and neck cancer module (QLQ-H&N35). Patients were divided into "severe-deterioration" and "mild-deterioration" groups on the basis of degree of deterioration HRQOL > 6 months after completing treatment. The relationships between HRQOL deteriorations and patient-related or dosimetry-related factors were evaluated. P < 0.0013 according to Bonferroni correction was considered to denote statistical significance. RESULTS: Regarding "trouble with social eating (HNSO)" and "coughing (HNCO)," there were significant differences between the severe-deterioration and mild-deterioration groups in mean dosages to the superior pharyngeal constrictor muscle (SPC) (HNSO: 62.5 Gy vs 54.2 Gy; p = 0.00029, and HNCO: 61.5 Gy vs 54.1 Gy; p = 0.0012) and parotid gland (HNSO: 24.1 Gy vs 20.5 Gy; p = 0.000056, and HNCO: 24.2 Gy vs 20.3 Gy; p = 0.00043). Regarding "nausea and vomiting," there was a significant difference between the two groups in the mean dosage to the middle pharyngeal constrictor muscle (MPC: 61.9 Gy vs. 58.4Gy; P = 0.00059). CONCLUSIONS: We found that dosages to the SPC and parotid gland were associated with severe deterioration in HRQOL attributable to difficulty in HNSO and HNCO, whereas dosage to the MPC was associated with severe deterioration attributable to nausea and vomiting.
引用
- Hayakawa T, Kawakami S, Soda I, et al. Dosimetric factors associated with long-term patient-reported outcomes after definitive radiotherapy of patients with head and neck cancer. Radiat Oncol. 2019. PMID: 31818301. doi:10.1186/s13014-019-1429-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。